Keyword: Revlimid

Bristol-Myers Squibb

1. Bristol-Myers Squibb/Celgene

The year 2019 kicked off with the biopharma industry’s largest acquisition proposal ever: Bristol-Myers Squibb unveiled it would buy Celgene in a cash and stock deal valued at $74 billion.